Radiotherapy-induced malignancies: Review of clinical features, pathobiology, and evolving approaches for mitigating risk

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Braunstein, Steve ^a   Nakamura, Jean L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer survivorship; Complications; Mutations; Radiation induced tumors; Second malignant neoplasms

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE;

ATOMIC BOMB SURVIVOR; BRAIN TUMOR; BREAST CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; COMPUTER ASSISTED RADIOTHERAPY; ENDOMETRIUM CANCER; GENE MUTATION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKEMIA; NEPHROBLASTOMA; NONHUMAN; PATHOLOGY; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; REVIEW; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER;

EID: 84890725078     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00073     Document Type: Review

References (185)

1. Adkins, D. R., and DiPersio, J. F. (2008). Total body irradiation before an allogeneic stem cell transplantation: Is there a magic dose? Curr. Opin. Hematol. 15, 555-560.
2. Agosteo, S., Birattari, C., Caravaggio, M., Silari, M., and Tosi, G. (1998). Secondary neutron and photon dose in proton therapy. Radiother. Oncol. 48, 293-305.
3. Albright, E. C., and Allday, R. W. (1967). Thyroid carcinoma after radiation therapy for adolescent acne vulgaris. JAMA 199, 280-281.
4. Aleman, B. M., Van den Belt-Dusebout, A. W., Klokman, W. J., Van't Veer, M. B., Bartelink, H., and Van Leeuwen, F. E. (2003). Long-term cause-specific mortality of patients treated for Hodgkin's disease. J. Clin. Oncol. 21, 3431-3439.
5. Allen, A. M., Pawlicki, T., Dong, L., Fourkal, E., Buyyounouski, M., Cengel, K., et al. (2012). An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. Radiother. Oncol. 103, 8-11.
6. Al-Mefty, O., Topsakal, C., Pravdenkova, S., Sawyer, J. R., and Harrison, M. J. (2004). Radiation-induced meningiomas: Clinical, pathological, cytokinetic, and cytogenetic characteristics. J. Neurosurg. 100, 1002-1013.
7. Armstrong, G. T., Liu, Q., Yasui, Y., Huang, S., Ness, K. K., Leisenring, W., et al. (2009a). Long-term outcomes among adult survivors of childhood central nervous system malignancies in the childhood cancer survivor study. J. Natl. Cancer Inst. 101, 946-958.
8. Armstrong, G. T., Liu, Q., Yasui, Y., Neglia, J. P., Leisenring, W., Robison, L. L., et al. (2009b). Late mortality among 5-year survivors of childhood cancer: A summary from the childhood cancer survivor study. J. Clin. Oncol. 27, 2328-2338.
9. Armstrong, G. T., Liu, W., Leisenring, W., Yasui, Y., Hammond, S., Bhatia, S., et al. (2011). Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study. J. Clin. Oncol. 29, 3056-3064.
10. Armstrong, G. T., Sklar, C. A., Hudson, M. M., and Robison, L. L. (2007). Long-term health status among survivors of childhood cancer: Does sex matter? J. Clin. Oncol. 25, 4477-4489.
11. Ashley, D. M., Merchant, T. E., Strother, D., Zhou, T., Duffner, P., Burger, P. C., et al. (2012). Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's oncology group study P9934. J. Clin. Oncol. 30, 3181-3186.
12. Athar, B. S., Bednarz, B., Seco, J., Hancox, C., and Paganetti, H. (2010). Comparison of out-of-field photon doses in 6 MV IMRT and neutron doses in proton therapy for adult and pediatric patients. Phys. Med. Biol. 55, 2879-2891.
13. Banerjee, J., Paakko, E., Harila, M., Herva, R., Tuominen, J., Koivula, A., et al. (2009). Radiation-induced meningiomas: A shadow in the success story of childhood leukemia. Neuro-oncology 11, 543-549.
14. Barcellos-Hoff, M. H. (1998). The potential influence of radiation-induced microenvironments in neoplastic progression. J. Mammary Gland Biol. Neoplasia 3, 165-175.
15. Barcellos-Hoff, M. H. (2005). Integrative radiation carcinogenesis: Interactions between cell and tissue responses to DNA damage. Semin. Cancer Biol. 15, 138-148.
16. Basu, S. K., Schwartz, C., Fisher, S. G., Hudson, M. M., Tarbell, N., Muhs, A., et al. (2008). Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 72, 34-40.
17. Best, T., Li, D., Skol, A. D., Kirchhoff, T., Jackson, S. A., Yasui, Y., et al. (2011). Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat. Med. 17, 941-943.
18. Bhatia, S., and Sklar, C. (2002). Second cancers in survivors of childhood cancer. Nat. Rev. Cancer 2, 124-132.
19. Boice, J. D. Jr., Blettner, M., Kleinerman, R. A., Stovall, M., Moloney, W. C., Engholm, G., et al. (1987). Radiation dose and leukemia risk in patients treated for cancer of the cervix. J. Natl. Cancer Inst. 79, 1295-1311.
20. Boice, J. D. Jr., Engholm, G., Kleinerman, R. A., Blettner, M., Stovall, M., Lisco, H., et al. (1988). Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat. Res. 116, 3-55.
21. Boorjian, S., Cowan, J. E., Konety, B. R., DuChane, J., Tewari, A., Carroll, P. R., et al. (2007). Bladder cancer incidence and risk factors in men with prostate cancer: Results from cancer of the prostate strategic urologic research endeavor. J Urol. 177, 883-887; discussion 7-8.
22. Brahme, A. (2001). Individualizing cancer treatment: Biological optimization models in treatment planning and delivery. Int. J. Radiat. Oncol. Biol. Phys. 49, 327-337.
23. Brahme, A. (2004). Recent advances in light ion radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 58, 603-616.
24. Brassesco, M. S., Valera, E. T., Neder, L., Pezuk, J. A., Oliveira, R. S., Scrideli, C. A., et al. (2012). Cytogenetic findings in pediatric radiation-induced atypical meningioma after treatment of medulloblastoma: Case report and review of the literature. J. Neurooncol. 110, 397-402.
25. Brenner, D. J., Curtis, R. E., Hall, E. J., and Ron, E. (2000). Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88, 398-406.
26. Brenner, D. J., and Hall, E. J. (2008). Secondary neutrons in clinical proton radiotherapy: A charged issue. Radiother. Oncol. 86, 165-170.
27. Breslow, N. E., Lange, J. M., Friedman, D. L., Green, D. M., Hawkins, M. M., Murphy, M. F., et al. (2010). Secondary malignant neoplasms after Wilms tumor: An international collaborative study. Int. J. Cancer 127, 657-666.
28. Brown, A. P., Neeley, E. S., Werner, T., Soisson, A. P., Burt, R. W., and Gaffney, D. K. A. (2010). population-based study of subsequent primary malignancies after endometrial cancer: Genetic, environmental, and treatment-related associations. Int. J. Radiat. Oncol. Biol. Phys. 78, 127-135.
29. Cahan, W. G., Woodward, H. Q., Higonbotham, N. L., Stewart, F. W., and Coley, B. L. (1948). Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1, 3-29.
30. Castellino, S. M., Geiger, A. M., Mertens, A. C., Leisenring, W. M., Tooze, J. A., Goodman, P., et al. (2011). Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the childhood cancer survivor study. Blood 117, 1806-1816.
31. Cella, L., Lomax, A., and Miralbell, R. (2001). New techniques in hadrontherapy: Intensity modulated proton beams. Phys. Med. 17(Suppl. 1), 100-102.
32. Chang, J. Y., Liu, H. H., and Komaki, R. (2005). Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr. Oncol. Rep. 7, 255-259.
33. Chaturvedi, A. K., Engels, E. A., Gilbert, E. S., Chen, B. E., Storm, H., Lynch, C. F., et al. (2007). Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk. J. Natl. Cancer Inst. 99, 1634-1643.
34. Chaves, A., Lopes, M. C., Alves, C. C., Oliveira, C., Peralta, L., Rodrigues, P., et al. (2004). A Monte Carlo multiple source model applied to radiosurgery narrow photon beams. Med. Phys. 31, 2192-2204.
35. Chera, B. S., Vargas, C., Morris, C. G., Louis, D., Flampouri, S., Yeung, D., et al. (2009). Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75, 994-1002.
36. Choi, G., Huang, B., Pinarbasi, E., Braunstein, S. E., Horvai, A. E., Kogan, S., et al. (2012). Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. Cancer Res. 72, 6425-6434.
37. Combs, S. E., Habermehl, D., Ganten, T., Schmidt, J., Edler, L., Burkholder, I., et al. (2011). Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial. BMC Cancer 11:67. doi:10.1186/1471-2407-11-67
38. Combs, S. E., Kieser, M., Habermehl, D., Weitz, J., Jager, D., Fossati, P., et al. (2012). Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: The PANDORA-01 trial. BMC Cancer 12:137. doi:10.1186/1471-2407-12-137
39. Combs, S. E., Kieser, M., Rieken, S., Habermehl, D., Jakel, O., Haberer, T., et al. (2010). Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA trial. BMC Cancer 10:478. doi:10.1186/1471-2407-10-478
40. Cooper, J. S., Pajak, T. F., Rubin, P., Tupchong, L., Brady, L. W., Leibel, S. A., et al. (1989). Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys. 17, 449-456.
41. Crump, M., and Hodgson, D. (2009). Secondary breast cancer in Hodgkin's lymphoma survivors. J. Clin. Oncol. 27, 4229-4231.
42. Das, I. J., Cheng, C. W., Fein, D. A., Coia, L. R., Curran, W. J. Jr., and Fowble, B. (1997). Dose estimation to critical organs from vertex field treatment of brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 37, 1023-1029.
43. De Bruin, M. L., Sparidans, J., Van't Veer, M. B., Noordijk, E. M., Louwman, M. W., Zijlstra, J. M., et al. (2009). Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J. Clin. Oncol. 27, 4239-4246.
44. Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., et al. (2002). Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484-3494.
45. Dorr, W., and Herrmann, T. (2002). Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. Strahlenther. Onkol. 178, 357-362.
46. Elbabaa, S. K., Gokden, M., Crawford, J. R., Kesari, S., and Saad, A. G. (2012). Radiation-associated meningiomas in children: Clinical, pathological, and cytogenetic characteristics with a critical review of the literature. J. Neurosurg. Pediatr. 10, 281-290.
47. Fontenot, J. D., Lee, A. K., and Newhauser, W. D. (2009). Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 74, 616-622.
48. Fontenot, J. D., Newhauser, W. D., and Titt, U. (2005). Design tools for proton therapy nozzles based on the double-scattering foil technique. Radiat. Prot. Dosimetry 116(Pt 2), 211-215.
49. Friedman, D. L., Whitton, J., Leisenring, W., Mertens, A. C., Hammond, S., Stovall, M., et al. (2010). Subsequent neoplasms in 5-year survivors of childhood cancer: the childhood cancer survivor study. J. Natl. Cancer Inst. 102, 1083-1095.
50. Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., et al. (2006). Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 7, 813-820.
51. Gilbert, E. S., Stovall, M., Gospodarowicz, M., Van Leeuwen, F. E., Andersson, M., Glimelius, B., et al. (2003). Lung cancer after treatment for Hodgkin's disease: Focus on radiation effects. Radiat. Res. 159, 161-173.
52. Ginsberg, J. P., Goodman, P., Leisenring, W., Ness, K. K., Meyers, P. A., Wolden, S. L., et al. (2010). Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J. Natl. Cancer Inst. 102, 1272-1283.
53. Goldstein, A. M., Yuen, J., and Tucker, M. A. (1997). Second cancers after medulloblastoma: Population-based results from the United States and Sweden. Cancer Causes Control 8, 865-871.
54. Gomez, D. R., and Chang, J. Y. (2011). Adaptive radiation for lung cancer. J. Oncol. 2011, doi:10.1155/2011/898391
55. Gregoire, V., Haustermans, K., Geets, X., Roels, S., and Lonneux, M. (2007). PET-based treatment planning in radiotherapy: A new standard? J. Nucl. Med. 48(Suppl. 1), 68S-77S.
56. Grozinger, S. O., Rietzel, E., Li, Q., Bert, C., Haberer, T., and Kraft, G. (2006). Simulations to design an online motion compensation system for scanned particle beams. Phys. Med. Biol. 51, 3517-3531.
57. Grutters, J. P., Kessels, A. G., Pijls-Johannesma, M., De Ruysscher, D., Joore, M. A., and Lambin, P. (2010). Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiother. Oncol. 95, 32-40.
58. Guibout, C., Adjadj, E., Rubino, C., Shamsaldin, A., Grimaud, E., Hawkins, M., et al. (2005). Malignant breast tumors after radiotherapy for a first cancer during childhood. J. Clin. Oncol. 23, 197-204.
59. Hall, E. J. (2006). Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65, 1-7.
60. Hall, E. J. (2009). Is there a place for quantitative risk assessment? J. Radiol. Prot. 29, A171-A84.
61. Hall, E. J., and Wuu, C. S. (2003). Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56, 83-88.
62. Hancock, S. L., Cox, R. S., and McDougall, I. R. (1991). Thyroid diseases after treatment of Hodgkin's disease. N. Engl. J. Med. 325, 599-605.
63. Harrison, M. J., Wolfe, D. E., Lau, T. S., Mitnick, R. J., and Sachdev, V. P. (1991). Radiation-induced meningiomas: Experience at the Mount Sinai Hospital and review of the literature. J. Neurosurg. 75, 564-574.
64. Heimers, A. (1999). Cytogenetic analysis in human lymphocytes after exposure to simulated cosmic radiation which reflects the inflight radiation environment. Int. J. Radiat. Biol. 75, 691-698.
65. Henderson, T. O., Whitton, J., Stovall, M., Mertens, A. C., Mitby, P., Friedman, D., et al. (2007). Secondary sarcomas in childhood cancer survivors: A report from the childhood cancer survivor study. J. Natl. Cancer Inst. 99, 300-308.
66. Hijiya, N., Ness, K. K., Ribeiro, R. C., and Hudson, M. M. (2009). Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues. Cancer 115, 23-35.
67. Hill-Kayser, C. E., Plastaras, J. P., Tochner, Z., and Glatstein, E. (2011). TBI during BM and SCT: Review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant. 46, 475-484.
68. Hisada, M., Garber, J. E., Fung, C. Y., Fraumeni, J. F. Jr., and Li, F. P. (1998). Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst. 90, 606-611.
69. Hodgson, D. C., Koh, E. S., Tran, T. H., Heydarian, M., Tsang, R., Pintilie, M., et al. (2007). Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110, 2576-2586.
70. Hooning, M. J., Aleman, B. M., Hauptmann, M., Baaijens, M. H., Klijn, J. G., Noyon, R., et al. (2008). Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J. Clin. Oncol. 26, 5561-5568.
71. Hui, Z., Zhang, X., Starkschall, G., Li, Y., Mohan, R., Komaki, R., et al. (2008). Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, 1385-1395.
72. Inskip, P. D., Stovall, M., and Flannery, J. T. (1994). Lung cancer risk and radiation dose among women treated for breast cancer. J. Natl. Cancer Inst. 86, 983-988.
73. Intensity Modulated Radiation Therapy Collaborative Working Group. (2001). Intensity-modulated radiotherapy: Current status and issues of interest. Int. J. Radiat. Oncol. Biol. Phys. 51, 880-914.
74. International Commission on Radiological Protection (ICRP). (1991). Recommendations of the International Commission on Radiological Protection. Oxford: Pegamon Press, Publication 60. Annals of ICRP 21.
75. Iwanaga, M., Hsu, W. L., Soda, M., Takasaki, Y., Tawara, M., Joh, T., et al. (2011). Risk of myelodysplastic syndromes in people exposed to ionizing radiation: A retrospective cohort study of Nagasaki atomic bomb survivors. J. Clin. Oncol. 29, 428-434.
76. Jiang, H., Wang, B., Xu, X. G., Suit, H. D., and Paganetti, H. (2005). Simulation of organ-specific patient effective dose due to secondary neutrons in proton radiation treatment. Phys. Med. Biol. 50, 4337-4353.
77. Jones, B. (2009). Modelling carcinogenesis after radiotherapy using Poisson statistics: Implications for IMRT, protons and ions. J. Radiol. Prot. 29, A143-A57.
78. Jones, B., and Burnet, N. (2005). Radiotherapy for the future. BMJ 330, 979-980.
79. Kellerer, A. M., Ruhm, W., and Walsh, L. (2006). Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors. Health Phys. 90, 554-564.
80. Kelly, K. M., and Perentesis, J. P. (2002). Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann. Oncol. 13(Suppl. 1), 34-39.
81. Kemp, C. J., Wheldon, T., and Balmain, A. (1994). p53-Deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8, 66-69.
82. Klein, E. E., Maserang, B., Wood, R., and Mansur, D. (2006). Peripheral doses from pediatric IMRT. Med. Phys. 33, 2525-2531.
83. Kleinerman, R. A. (2009). Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr. Radiol. 39(Suppl. 1), S27-S31.
84. Kleinschmidt-DeMasters, B. K., and Lillehei, K. O. (1995). Radiation-induced meningioma with a 63-year latency period. Case report. J. Neurosurg. 82, 487-488.
85. Koay, E. J., Lege, D., Mohan, R., Komaki, R., Cox, J. D., and Chang, J. Y. (2012). Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 1093-1100.
86. Koh, E. S., Tran, T. H., Heydarian, M., Sachs, R. K., Tsang, R. W., Brenner, D. J., et al. (2007). A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: Reduction in normal tissue dose and second cancer risk. Radiat. Oncol. 2, 13.
87. Kry, S. F., Salehpour, M., Followill, D. S., Stovall, M., Kuban, D. A., White, R. A., et al. (2005a). Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 1204-1216.
88. Kry, S. F., Salehpour, M., Followill, D. S., Stovall, M., Kuban, D. A., White, R. A., et al. (2005b). The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 1195-1203.
89. Laverdiere, C., Liu, Q., Yasui, Y., Nathan, P. C., Gurney, J. G., Stovall, M., et al. (2009). Long-term outcomes in survivors of neuroblastoma: A report from the childhood cancer survivor study. J. Natl. Cancer Inst. 101, 1131-1140.
90. Lee, C. T., Bilton, S. D., Famiglietti, R. M., Riley, B. A., Mahajan, A., Chang, E. L., et al. (2005). Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques? Int. J. Radiat. Oncol. Biol. Phys. 63, 362-372.
91. Li, F. P., Cassady, J. R., and Barnett, E. (1974). Cancer mortality following irradiation in infancy for hemangioma. Radiology 113, 177-178.
92. Liauw, S. L., Sylvester, J. E., Morris, C. G., Blasko, J. C., and Grimm, P. D. (2006). Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int. J. Radiat. Oncol. Biol. Phys. 66, 669-673.
93. Little, M. P. (1997). Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors. Int. J. Radiat. Biol. 72, 715-726.
94. Lloyd, D. C., Purrott, R. J., Dolphin, G. W., and Edwards, A. A. (1976). Chromosome aberrations induced in human lymphocytes by neutron irradiation. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 29, 169-182.
95. Lomax, A. J., Bohringer, T., Bolsi, A., Coray, D., Emert, F., Goitein, G., et al. (2004). Treatment planning and verification of proton therapy using spot scanning: Initial experiences. Med. Phys. 31, 3150-3157.
96. Lomax, A. J., Bortfeld, T., Goitein, G., Debus, J., Dykstra, C., Tercier, P. A., et al. (1999). A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother. Oncol. 51, 257-271.
97. Lubin, J. H., Purdue, M., Kelsey, K., Zhang, Z. F., Winn, D., Wei, Q., et al. (2009). Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: A pooled analysis of case-control studies. Am. J. Epidemiol. 170, 937-947.
98. MacArthur, A. C., Spinelli, J. J., Rogers, P. C., Goddard, K. J., Abanto, Z. U., and McBride, M. L. (2007). Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada. Pediatr. Blood Cancer 48, 460-467.
99. Mackie, T. R., and Tome, W. (2008). Advanced image-guided external beam radiotherapy. Cancer Treat. Res. 139, 7-39.
100. Major, I. R., and Mole, R. H. (1978). Myeloid leukaemia in x-ray irradiated CBA mice. Nature 272, 455-456.
101. Malkin, D., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., et al. (1992). Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N. Engl. J. Med. 326, 1309-1315.
102. Mancuso, M., Pasquali, E., Leonardi, S., Rebessi, S., Tanori, M., Giardullo, P., et al. (2011). Role of connexin43 and ATP in long-range bystander radiation damage and oncogenesis in vivo. Oncogene 30, 4601-4608.
103. Mao, J. H., Li, J., Jiang, T., Li, Q., Wu, D., Perez-Losada, J., et al. (2005). Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice. Oncogene 24, 7924-7934.
104. Mao, J. H., Wu, D., DelRosario, R., Castellanos, A., Balmain, A., and Perez-Losada, J. (2008). Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background. Oncogene 27, 6596-6600.
105. Mazonakis, M., Damilakis, J., Varveris, H., Fasoulaki, M., and Gourtsoyiannis, N. (2003). Risk estimation of radiation-induced thyroid cancer from treatment of brain tumors in adults and children. Int. J. Oncol. 22, 221-225.
106. Meadows, A. T., Friedman, D. L., Neglia, J. P., Mertens, A. C., Donaldson, S. S., Stovall, M., et al. (2009). Second neoplasms in survivors of childhood cancer: Findings from the childhood cancer survivor study cohort. J. Clin. Oncol. 27, 2356-2362.
107. Merchant, T. E. (2009). Proton beam therapy in pediatric oncology. Cancer J. 15, 298-305.
108. Mertens, A. C., Mitby, P. A., Radloff, G., Jones, I. M., Perentesis, J., Kiffmeyer, W. R., et al. (2004). XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 101, 1463-1472.
109. Milano, M. T., Li, H., Gail, M. H., Constine, L. S., and Travis, L. B. (2010). Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: A population-based study. J. Clin. Oncol. 28, 5088-5096.
110. Miralbell, R., Lomax, A., Cella, L., and Schneider, U. (2002). Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int. J. Radiat. Oncol. Biol. Phys. 54, 824-829.
111. Mitaroff, A., and Cern, M. S. (2002). The CERN-EU high-energy reference field (CERF) facility for dosimetry at commercial flight altitudes and in space. Radiat. Prot. Dosimetry 102, 7-22.
112. Modan, B., Baidatz, D., Mart, H., Steinitz, R., and Levin, S. G. (1974). Radiation-induced head and neck tumours. Lancet 1, 277-279.
113. Monje, M. L., and Palmer, T. (2003). Radiation injury and neurogenesis. Curr. Opin. Neurol. 16, 129-134.
114. Mothersill, C., and Seymour, C. B. (2004). Radiation-induced bystander effects-implications for cancer. Nat. Rev. Cancer 4, 158-164.
115. Nakamura, J. L., Phong, C., Pinarbasi, E., Kogan, S. C., Vandenberg, S., Horvai, A. E., et al. (2011). Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res. 71, 106-115.
116. Nath, R., Epp, E. R., Laughlin, J. S., Swanson, W. P., and Bond, V. P. (1984). Neutrons from high-energy x-ray medical accelerators: An estimate of risk to the radiotherapy patient. Med. Phys. 11, 231-241.
117. National Council on Radiation Protection and Measurements (NCRP). (1990). The Relative Biological Effectiveness of Radiations of Different Quality. Report No. 104. Bethesda: NCRP.
118. National Research Council. (2006). Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII-Phase 2. Washington, DC: National Academies Press.
119. Neglia, J. P., Meadows, A. T., Robison, L. L., Kim, T. H., Newton, W. A., Ruymann, F. B., et al. (1991). Second neoplasms after acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 325, 1330-1336.
120. Neglia, J. P., Robison, L. L., Stovall, M., Liu, Y., Packer, R. J., Hammond, S., et al. (2006). New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl. Cancer Inst. 98, 1528-1537.
121. Newhauser, W. D., Fontenot, J. D., Mahajan, A., Kornguth, D., Stovall, M., Zheng, Y., et al. (2009). The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys. Med. Biol. 54, 2277-2291.
122. Nguyen, D. H., Oketch-Rabah, H. A., Illa-Bochaca, I., Geyer, F. C., Reis-Filho, J. S., Mao, J. H., et al. (2011). Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell 19, 640-651.
123. Nieder, A. M., Porter, M. P., and Soloway, M. S. (2008). Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: A population based cohort study. J. Urol. 180, 2005-2009; discussion 9-10.
124. Photon Treatment Planning Collaborative Working Group. (1991a). Evaluation of high energy photon external beam treatment planning: Project summary. Int. J. Radiat. Oncol. Biol. Phys. 21, 3-8.
125. Photon Treatment Planning Collaborative Working Group. (1991b). State-of-the-art of external photon beam radiation treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 21, 9-23.
126. Pierce, D. A., Shimizu, Y., Preston, D. L., Vaeth, M., and Mabuchi, K. (1996). Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat. Res. 146, 1-27.
127. Preston, D. L., Ron, E., Yonehara, S., Kobuke, T., Fujii, H., Kishikawa, M., et al. (2002). Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J. Natl. Cancer Inst. 94, 1555-1563.
128. Preston, D. L., Shimizu, Y., Pierce, D. A., Suyama, A., and Mabuchi, K. (2003). Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat. Res. 160, 381-407.
129. Purdy, J. A. (2008). Dose to normal tissues outside the radiation therapy patient's treated volume: A review of different radiation therapy techniques. Health Phys. 95, 666-676.
130. Rienstein, S., Loven, D., Israeli, O., Ram, Z., Rappaport, Z. H., Barkai, G., et al. (2001). Comparative genomic hybridization analysis of radiation-associated and sporadic meningiomas. Cancer Genet. Cytogenet. 131, 135-140.
131. Rizzo, J. D., Curtis, R. E., Socie, G., Sobocinski, K. A., Gilbert, E., Landgren, O., et al. (2009). Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113, 1175-1183.
132. Rodrigues, P., Trindade, A., Peralta, L., Alves, C., Chaves, A., and Lopes, M. C. (2004). Application of GEANT4 radiation transport toolkit to dose calculations in anthropomorphic phantoms. Appl. Radiat. Isot. 61, 1451-1461.
133. Ron, E., Modan, B., and Boice, J. D. Jr. (1988a). Mortality after radiotherapy for ringworm of the scalp. Am. J. Epidemiol. 127, 713-725.
134. Ron, E., Modan, B., Boice, J. D. Jr., Alfandary, E., Stovall, M., Chetrit, A., et al. (1988b). Tumors of the brain and nervous system after radiotherapy in childhood. N. Engl. J. Med. 319, 1033-1039.
135. Ron, E., Preston, D. L., Mabuchi, K., Thompson, D. E., and Soda, M. (1994). Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality. Radiat. Res. 137(Suppl. 2), S98-S112.
136. Ruben, J. D., Davis, S., Evans, C., Jones, P., Gagliardi, F., Haynes, M., et al. (2008). The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. Int. J. Radiat. Oncol. Biol. Phys. 70, 1530-1536.
137. Rubino, C., de Vathaire, F., Diallo, I., Shamsaldin, A., Grimaud, E., Labbe, M., et al. (2002). Radiation dose, chemotherapy and risk of lung cancer after breast cancer treatment. Breast Cancer Res. Treat. 75, 15-24.
138. Rutkowski, S., Gerber, N. U., von Hoff, K., Gnekow, A., Bode, U., Graf, N., et al. (2009). Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-oncology 11, 201-210.
139. Sadamori, N., Shibata, S., Mine, M., Miyazaki, H., Miyake, H., Kurihara, M., et al. (1996). Incidence of intracranial meningiomas in Nagasaki atomic-bomb survivors. Int. J. Cancer 67, 318-322.
140. Sage, J. (2012). The retinoblastoma tumor suppressor and stem cell biology. Genes Dev. 26, 1409-1420.
141. Sasse, S., Klimm, B., Gorgen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., et al. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended-or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann. Oncol. 23, 2953-2959.
142. Schmid, C., Schleuning, M., Ledderose, G., Tischer, J., and Kolb, H. J. (2005). Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23, 5675-5687.
143. Schneider, U. (2005). Dose-response relationship for radiation-induced cancer-decrease or plateau at high dose: In regard to Davis (Int J Radiat Oncol Biol Phys 2004;59:916). Int. J. Radiat. Oncol. Biol. Phys. 61, 312-313; author reply 3.
144. Schneider, U., Agosteo, S., Pedroni, E., and Besserer, J. (2002). Secondary neutron dose during proton therapy using spot scanning. Int. J. Radiat. Oncol. Biol. Phys. 53, 244-251.
145. Schneider, U., and Kaser-Hotz, B. (2005). Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau dose-response relationships. Radiat. Environ. Biophys. 44, 235-239.
146. Schneider, U., Lomax, A., Besserer, J., Pemler, P., Lombriser, N., and Kaser-Hotz, B. (2007). The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 892-897.
147. Schneider, U., Lomax, A., and Lombriser, N. (2000). Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation. Radiat. Res. 154, 382-388.
148. Schneider, U., Lomax, A., and Lombriser, N. (2001). Comparative treatment planning using secondary cancer mortality calculations. Phys. Med. 17(Suppl. 1), 97-99.
149. Schneider, U., Lomax, A., Pemler, P., Besserer, J., Ross, D., Lombriser, N., et al. (2006). The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther. Onkol. 182, 647-652.
150. Schneider, U., Zwahlen, D., Ross, D., and Kaser-Hotz, B. (2005). Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose. Int. J. Radiat. Oncol. Biol. Phys. 61, 1510-1515.
151. Shamisa, A., Bance, M., Nag, S., Tator, C., Wong, S., Noren, G., et al. (2001). Glioblastoma multiforme occurring in a patient treated with gamma knife surgery. Case report and review of the literature. J. Neurosurg. 94, 816-821.
152. Sharif, S., Ferner, R., Birch, J. M., Gillespie, J. E., Gattamaneni, H. R., Baser, M. E., et al. (2006). Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: Substantial risks after radiotherapy. J. Clin. Oncol. 24, 2570-2575.
153. Shewach, D. S., and Lawrence, T. S. (2007). Antimetabolite radiosensitizers. J. Clin. Oncol. 25, 4043-4050.
154. Shin, D., Yoon, M., Kwak, J., Shin, J., Lee, S. B., Park, S. Y., et al. (2009). Secondary neutron doses for several beam configurations for proton therapy. Int. J. Radiat. Oncol. Biol. Phys. 74, 260-265.
155. Shuryak, I., Sachs, R. K., and Brenner, D. J. (2007). Biophysical models of radiation bystander effects: 1. Spatial effects in three-dimensional tissues. Radiat. Res. 168, 741-749.
156. Shuryak, I., Sachs, R. K., and Brenner, D. J. (2010). Cancer risks after radiation exposure in middle age. J. Natl. Cancer Inst. 102, 1628-1636.
157. Shuryak, I., Sachs, R. K., and Brenner, D. J. (2011). A new view of radiation-induced cancer. Radiat. Prot. Dosimetry 143, 358-364.
158. Smith, P. G., and Doll, R. (1982). Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br. Med. J. (Clin. Res. Ed.) 284, 449-460.
159. Song, W., Schaly, B., Bauman, G., Battista, J., and Van Dyk, J. (2005). Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Med. Phys. 32, 2193-2203.
160. Taddei, P. J., Mahajan, A., Mirkovic, D., Zhang, R., Giebeler, A., Kornguth, D., et al. (2010). Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation. Phys. Med. Biol. 55, 7067-7080.
161. Taddei, P. J., Mirkovic, D., Fontenot, J. D., Giebeler, A., Zheng, Y., Kornguth, D., et al. (2009). Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys. Med. Biol. 54, 2259-2275.
162. Taylor, A. J., Little, M. P., Winter, D. L., Sugden, E., Ellison, D. W., Stiller, C. A., et al. (2010). Population-based risks of CNS tumors in survivors of childhood cancer: The British childhood cancer survivor study. J. Clin. Oncol. 28, 5287-5293.
163. Thomas, C. T., Ammar, A., Farrell, J. J., and Elsaleh, H. (2006). Radiation modifiers: treatment overview and future investigations. Hematol. Oncol. Clin. North Am. 20, 119-139.
164. Thompson, D. E., Mabuchi, K., Ron, E., Soda, M., Tokunaga, M., Ochikubo, S., et al. (1994). Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987. Radiat. Res. 137(Suppl. 2), S17-S67.
165. Travis, L. B., Curtis, R. E., Boice, J. D. Jr., Platz, C. E., Hankey, B. F., and Fraumeni, J. F. Jr. (1996). Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res. 56, 1564-1570.
166. Travis, L. B., Hill, D., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., et al. (2005a). Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J. Natl. Cancer Inst. 97, 1428-1437.
167. Travis, L. B., Fossa, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., et al. (2005b). Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J. Natl. Cancer Inst. 97, 1354-1365.
168. Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., et al. (2003). Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290, 465-475.
169. Travis, L. B., Ng, A. K., Allan, J. M., Pui, C. H., Kennedy, A. R., Xu, X. G., et al. (2012). Second malignant neoplasms and cardiovascular disease following radiotherapy. J. Natl. Cancer Inst. 104, 357-370.
170. Tsujii, H., Mizoe, J. E., Kamada, T., Baba, M., Kato, S., Kato, H., et al. (2004). Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother. Oncol. 73(Suppl. 2), S41-S49.
171. Tucker, M. A., D'Angio, G. J., Boice, J. D. Jr., Strong, L. C., Li, F. P., Stovall, M., et al. (1987). Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med. 317, 588-593.
172. Tukenova, M., Guibout, C., Hawkins, M., Quiniou, E., Mousannif, A., Pacquement, H., et al. (2011). Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int. J. Radiat. Oncol. Biol. Phys. 80, 339-346.
173. Ullrich, R. L., Bowles, N. D., Satterfield, L. C., and Davis, C. M. (1996). Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiat. Res. 146, 353-355.
174. Ullrich, R. L., Jernigan, M. C., Satterfield, L. C., and Bowles, N. D. (1987). Radiation carcinogenesis: Time-dose relationships. Radiat. Res. 111, 179-184.
175. Underwood, J. M., Townsend, J. S., Stewart, S. L., Buchannan, N., Ekwueme, D. U., Hawkins, N. A., et al. (2012). Surveillance of demographic characteristics and health behaviors among adult cancer survivors-behavioral risk factor surveillance system, United States, 2009. MMWR Surveill. Summ. 61, 1-23.
176. Van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W., Ribot, J. G., et al. (2007). Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370-4378.
177. Verellen, D., and Vanhavere, F. (1999). Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother. Oncol. 53, 199-203.
178. Widel, M., Przybyszewski, W. M., Cieslar-Pobuda, A., Saenko, Y. V., and Rzeszowska-Wolny, J. (2012). Bystander normal human fibroblasts reduce damage response in radiation targeted cancer cells through intercellular ROS level modulation. Mutat. Res. 731, 117-124.
179. Wiezorek, T., Schwahofer, A., and Schubert, K. (2009). The influence of different IMRT techniques on the peripheral dose: A comparison between sMLM-IMRT and helical tomotherapy. Strahlenther. Onkol. 185, 696-702.
180. Wolden, S. L., Lamborn, K. R., Cleary, S. F., Tate, D. J., and Donaldson, S. S. (1998). Second cancers following pediatric Hodgkin's disease. J. Clin. Oncol. 16, 536-544.
181. Wong, F. L., Boice, J. D. Jr., Abramson, D. H., Tarone, R. E., Kleinerman, R. A., Stovall, M., et al. (1997). Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278, 1262-1267.
182. Wu, V. W., Law, M. Y., Star-Lack, J., Cheung, F. W., and Ling, C. C. (2011). Technologies of image guidance and the development of advanced linear accelerator systems for radiotherapy. Front. Radiat. Ther. Oncol. 43, 132-164.
183. Yu, J. S., Yong, W. H., Wilson, D., and Black, K. L. (2000). Glioblastoma induction after radiosurgery for meningioma. Lancet 356, 1576-1577.
184. Zacharatou Jarlskog, C., and Paganetti, H. (2008). Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. Int. J. Radiat. Oncol. Biol. Phys. 72, 228-235.
185. Zelefsky, M. J., Housman, D. M., Pei, X., Alicikus, Z., Magsanoc, J. M., Dauer, L. T., et al. (2012). Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 83, 953-959.